MindWalk Holdings Corp. (NASDAQ:HYFT) Given Consensus Rating of "Hold" by Analysts

Key Points

• Analysts hold a mixed view of MindWalk: The stock has a consensus “Hold” rating from five analysts, with two sells, two buys, and one strong buy. The average 12-month price target is $5.00, compared with a recent price of $1.30.
• Recent financial results were weak: MindWalk reported a quarterly loss of $0.06 per share, missing the consensus estimate by $0.01, on $3.03 million in revenue. The company posted an 89.65% negative net margin and analysts expect a full-year loss of $0.21 per share.
• MindWalk’s market capitalization is approximately $60.96 million, while hedge funds and other institutional investors own 6.70% of its shares. The stock has traded between $0.99 and $2.99 over the past year.

MindWalk Holdings Corp. (NASDAQ:HYFT - Get Free Report) has been assigned an average recommendation of "Hold" from the five brokerages that are covering the stock, Marketbeat reports. Two research analysts have rated the stock with a sell recommendation, two have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price target among analysts that have covered the stock in the last year is $5.00.

Several analysts have issued reports on HYFT shares. Weiss Ratings reissued a "sell (e+)" rating on shares of MindWalk in a report on Wednesday, July 15th. Wall Street Zen raised MindWalk from a "sell" rating to a "hold" rating in a research report on Saturday, August 15th. Zacks Research downgraded MindWalk from a "hold" rating to a "strong sell" rating in a research note on Tuesday, July 28th. Finally, HC Wainwright restated a "buy" rating on shares of MindWalk in a research note on Monday, July 20th.

MindWalk Stock Down 1.1%

HYFT opened at $1.30 on Friday. The firm's 50 day simple moving average is $1.38 and its two-hundred day simple moving average is $1.36. The company has a market capitalization of $60.96 million, a PE ratio of -5.93 and a beta of 0.82. MindWalk has a 1-year low of $0.99 and a 1-year high of $2.99. The company has a current ratio of 2.80, a quick ratio of 2.72 and a debt-to-equity ratio of 0.26.

MindWalk (NASDAQ:HYFT - Get Free Report) last issued its quarterly earnings data on Wednesday, July 22nd. The company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.05) by ($0.01). The business had revenue of $3.03 million for the quarter. MindWalk had a negative net margin of 89.65% and a negative return on equity of 92.61%. As a group, equities analysts forecast that MindWalk will post -0.21 EPS for the current year.

Institutional Trading of MindWalk

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Virtu Financial LLC purchased a new position in shares of MindWalk during the 4th quarter valued at $51,000. GSA Capital Partners LLP purchased a new stake in MindWalk in the 2nd quarter worth $55,000. Bridgeway Capital Management LLC purchased a new stake in MindWalk in the 4th quarter worth $91,000. Bank of Montreal Can raised its holdings in MindWalk by 81.0% during the fourth quarter. Bank of Montreal Can now owns 54,750 shares of the company's stock valued at $100,000 after acquiring an additional 24,500 shares during the period. Finally, XTX Topco Ltd raised its holdings in MindWalk by 118.6% during the fourth quarter. XTX Topco Ltd now owns 81,721 shares of the company's stock valued at $149,000 after acquiring an additional 44,331 shares during the period. 6.70% of the stock is owned by hedge funds and other institutional investors.

MindWalk Company Profile

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.